Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 13 | 2024 | 204 | 1.380 |
Why?
|
| Immunologic Factors | 5 | 2014 | 99 | 0.990 |
Why?
|
| Demyelinating Diseases | 2 | 2014 | 14 | 0.830 |
Why?
|
| Neuromyelitis Optica | 2 | 2011 | 4 | 0.760 |
Why?
|
| Cervical Cord | 1 | 2020 | 5 | 0.730 |
Why?
|
| Spondylosis | 1 | 2020 | 27 | 0.700 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2014 | 60 | 0.660 |
Why?
|
| Papillomavirus Vaccines | 2 | 2010 | 71 | 0.650 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 2 | 2012 | 57 | 0.470 |
Why?
|
| Fumarates | 1 | 2014 | 9 | 0.470 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2024 | 2015 | 0.460 |
Why?
|
| Interferons | 1 | 2014 | 64 | 0.450 |
Why?
|
| Psoriasis | 1 | 2014 | 51 | 0.450 |
Why?
|
| Interferon-beta | 2 | 2011 | 76 | 0.440 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 291 | 0.410 |
Why?
|
| Antiviral Agents | 1 | 2014 | 314 | 0.380 |
Why?
|
| Gene Expression Profiling | 4 | 2013 | 695 | 0.380 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2011 | 32 | 0.380 |
Why?
|
| Tremor | 1 | 2011 | 20 | 0.370 |
Why?
|
| Head | 1 | 2011 | 52 | 0.360 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 1 | 2010 | 3 | 0.350 |
Why?
|
| Reflex, Abnormal | 1 | 2010 | 3 | 0.350 |
Why?
|
| Sarcoidosis | 1 | 2010 | 27 | 0.350 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2007 | 291 | 0.330 |
Why?
|
| Nervous System Diseases | 1 | 2010 | 94 | 0.320 |
Why?
|
| Parkinson Disease | 1 | 2010 | 97 | 0.320 |
Why?
|
| Vaccination | 1 | 2010 | 335 | 0.300 |
Why?
|
| Cognition Disorders | 1 | 2010 | 217 | 0.300 |
Why?
|
| Peptides | 1 | 2011 | 546 | 0.300 |
Why?
|
| Adult | 12 | 2024 | 15640 | 0.300 |
Why?
|
| Rituximab | 4 | 2014 | 82 | 0.300 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 864 | 0.260 |
Why?
|
| Female | 18 | 2024 | 30640 | 0.260 |
Why?
|
| Positron-Emission Tomography | 1 | 2024 | 170 | 0.220 |
Why?
|
| Genetic Heterogeneity | 1 | 2003 | 23 | 0.220 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2003 | 27 | 0.220 |
Why?
|
| Humans | 25 | 2024 | 58964 | 0.220 |
Why?
|
| Male | 14 | 2024 | 27346 | 0.210 |
Why?
|
| Middle Aged | 8 | 2024 | 16172 | 0.200 |
Why?
|
| Biomarkers | 2 | 2014 | 1201 | 0.170 |
Why?
|
| B-Lymphocytes | 2 | 2014 | 549 | 0.170 |
Why?
|
| Spinal Cord | 1 | 2020 | 195 | 0.170 |
Why?
|
| Brain | 3 | 2011 | 1477 | 0.150 |
Why?
|
| Treatment Outcome | 4 | 2014 | 5119 | 0.150 |
Why?
|
| Gene Expression Regulation | 2 | 2007 | 1535 | 0.150 |
Why?
|
| Retrospective Studies | 3 | 2020 | 5941 | 0.140 |
Why?
|
| Natalizumab | 1 | 2016 | 10 | 0.130 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2016 | 18 | 0.130 |
Why?
|
| Disease Progression | 2 | 2011 | 1032 | 0.130 |
Why?
|
| Cohort Studies | 2 | 2020 | 2429 | 0.130 |
Why?
|
| Interleukin-10 | 2 | 2014 | 143 | 0.120 |
Why?
|
| Dimethyl Fumarate | 1 | 2014 | 8 | 0.120 |
Why?
|
| Myasthenia Gravis | 1 | 2014 | 8 | 0.120 |
Why?
|
| Recurrence | 2 | 2016 | 575 | 0.110 |
Why?
|
| Twins | 2 | 2006 | 52 | 0.110 |
Why?
|
| Signal Transduction | 1 | 2003 | 2881 | 0.110 |
Why?
|
| Integrin alpha4 | 1 | 2012 | 3 | 0.100 |
Why?
|
| Glatiramer Acetate | 1 | 2011 | 6 | 0.100 |
Why?
|
| Genetic Linkage | 3 | 2003 | 101 | 0.100 |
Why?
|
| Neutrophil Infiltration | 1 | 2012 | 61 | 0.100 |
Why?
|
| Antibodies | 1 | 2012 | 176 | 0.090 |
Why?
|
| Th2 Cells | 1 | 2011 | 98 | 0.090 |
Why?
|
| Immunoglobulin E | 1 | 2011 | 85 | 0.090 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 146 | 0.090 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2010 | 8 | 0.090 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2010 | 1 | 0.090 |
Why?
|
| Killer Cells, Natural | 1 | 2012 | 215 | 0.090 |
Why?
|
| Risk Factors | 1 | 2020 | 4981 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 453 | 0.090 |
Why?
|
| Autoantibodies | 1 | 2011 | 174 | 0.090 |
Why?
|
| Central Nervous System | 1 | 2012 | 190 | 0.090 |
Why?
|
| Electric Stimulation | 1 | 2010 | 139 | 0.080 |
Why?
|
| RNA | 1 | 2013 | 400 | 0.080 |
Why?
|
| Immunoglobulin G | 1 | 2011 | 450 | 0.080 |
Why?
|
| Functional Laterality | 1 | 2010 | 133 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 2 | 2012 | 3168 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2013 | 617 | 0.070 |
Why?
|
| Twin Studies as Topic | 1 | 2006 | 15 | 0.070 |
Why?
|
| Italy | 5 | 2006 | 62 | 0.060 |
Why?
|
| Genetic Markers | 2 | 2003 | 120 | 0.060 |
Why?
|
| Carbon Radioisotopes | 1 | 2024 | 11 | 0.060 |
Why?
|
| Aged | 1 | 2020 | 13250 | 0.060 |
Why?
|
| Receptors, GABA | 1 | 2024 | 12 | 0.060 |
Why?
|
| Muscle, Skeletal | 1 | 2010 | 668 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2024 | 123 | 0.060 |
Why?
|
| Linkage Disequilibrium | 1 | 2003 | 49 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2003 | 1048 | 0.060 |
Why?
|
| White Matter | 1 | 2024 | 113 | 0.050 |
Why?
|
| Receptors, Prolactin | 1 | 2003 | 6 | 0.050 |
Why?
|
| Prolactin | 1 | 2003 | 40 | 0.050 |
Why?
|
| Pedigree | 1 | 2003 | 190 | 0.050 |
Why?
|
| Time Factors | 1 | 2010 | 3551 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2003 | 132 | 0.050 |
Why?
|
| Genome, Human | 1 | 2003 | 217 | 0.050 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2003 | 156 | 0.050 |
Why?
|
| Mice | 2 | 2012 | 10210 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2003 | 222 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 2003 | 957 | 0.050 |
Why?
|
| Phenotype | 1 | 2024 | 1151 | 0.050 |
Why?
|
| Base Sequence | 1 | 2003 | 1309 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2003 | 458 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2000 | 17 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 5057 | 0.040 |
Why?
|
| Family Health | 1 | 2000 | 68 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 1972 | 0.040 |
Why?
|
| Adolescent | 1 | 2010 | 5879 | 0.040 |
Why?
|
| Animals | 3 | 2013 | 19519 | 0.040 |
Why?
|
| Myelin Basic Protein | 1 | 1999 | 23 | 0.040 |
Why?
|
| Immune System | 1 | 2000 | 129 | 0.040 |
Why?
|
| Antigens | 1 | 1999 | 146 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 1 | 1999 | 177 | 0.040 |
Why?
|
| Inflammation | 1 | 2024 | 1096 | 0.040 |
Why?
|
| Epitopes | 1 | 1999 | 298 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1999 | 276 | 0.040 |
Why?
|
| Alleles | 3 | 2003 | 424 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2006 | 672 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 280 | 0.030 |
Why?
|
| Peptide Fragments | 2 | 2012 | 351 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2016 | 130 | 0.030 |
Why?
|
| Gene Frequency | 2 | 2003 | 131 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 2316 | 0.030 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2012 | 10 | 0.030 |
Why?
|
| Microsatellite Repeats | 2 | 2003 | 37 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2013 | 248 | 0.020 |
Why?
|
| Genotype | 2 | 2003 | 641 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 238 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 304 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 501 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2012 | 192 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2012 | 341 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 419 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 667 | 0.020 |
Why?
|
| Filamins | 1 | 2007 | 7 | 0.020 |
Why?
|
| Interferon beta-1a | 1 | 2007 | 9 | 0.020 |
Why?
|
| Contractile Proteins | 1 | 2007 | 14 | 0.020 |
Why?
|
| Interleukin-16 | 1 | 2007 | 24 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2014 | 3078 | 0.020 |
Why?
|
| Caenorhabditis elegans | 1 | 2013 | 613 | 0.020 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2007 | 79 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2007 | 116 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2006 | 158 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 2046 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2006 | 485 | 0.010 |
Why?
|
| Homeostasis | 1 | 2007 | 335 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 4284 | 0.010 |
Why?
|
| International Cooperation | 1 | 2003 | 84 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2003 | 7 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2003 | 16 | 0.010 |
Why?
|
| 5' Untranslated Regions | 1 | 2003 | 23 | 0.010 |
Why?
|
| Introns | 1 | 2003 | 106 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2003 | 251 | 0.010 |
Why?
|
| Exons | 1 | 2003 | 192 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 498 | 0.010 |
Why?
|
| HLA-DRB1 Chains | 1 | 2000 | 12 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 2000 | 27 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2000 | 31 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1999 | 112 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 2567 | 0.010 |
Why?
|
| Cell Line | 1 | 1999 | 2011 | 0.010 |
Why?
|